(RTTNews) - Lantern Pharma Inc. (LTRN), a clinical-stage biotechnology company, on Wednesday shared additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184.
The trial showed encouraging, durable disease control in heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair (DDR) pathway deficiencies. The study met all primary endpoints for safety and tolerability.
Lantern said it plans to advance LP-184 into multiple Phase 1b/2 trials.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
